Iovance Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:IOVA Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
23 May 25	BuyUS$9,743	Raj Puri	Individual		5,600	US$1.74
14 May 25	BuyUS$42,250	Frederick Vogt	Individual		25,000	US$1.69

Insider Trading Volume

Insider Buying: IOVA insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of IOVA?
Owner Type	Number of Shares	Ownership Percentage
VC/PE Firms	24,417,103	7.31%
Individual Insiders	29,082,542	8.71%
General Public	61,292,447	18.4%
Institutions	219,142,295	65.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.3%.

Top Shareholders

Top 25 shareholders own 66.31% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
8.41%	Wayne Rothbaum	28,067,333	US$50.0m	0%	no data
8.32%	The Vanguard Group, Inc.	27,777,778	US$49.4m	0.88%	no data
7.31%	MHR Fund Management LLC	24,417,103	US$43.5m	0%	5.77%
7.28%	BlackRock, Inc.	24,314,371	US$43.3m	3.57%	no data
3.81%	Perceptive Advisors LLC	12,711,788	US$22.6m	-42.5%	0.84%
3.31%	State Street Global Advisors, Inc.	11,041,322	US$19.7m	-9.86%	no data
2.77%	Long Focus Capital Management LLC	9,250,055	US$16.5m	80.2%	1.1%
2.76%	Hood River Capital Management LLC	9,216,040	US$16.4m	2.5%	0.26%
2.48%	UBS Asset Management AG	8,274,093	US$14.7m	79.4%	no data
2.33%	Soleus Capital Management, L.P.	7,785,000	US$13.9m	18.7%	0.98%
1.79%	Geode Capital Management, LLC	5,968,298	US$10.6m	1.65%	no data
1.64%	Invenomic Capital Management LP	5,489,799	US$9.8m	0%	0.76%
1.54%	Goldman Sachs Group, Investment Banking and Securities Investments	5,148,908	US$9.2m	37.9%	no data
1.43%	Macquarie Investment Management Business Trust	4,791,235	US$8.5m	0.85%	0.01%
1.41%	Principal Global Investors, LLC	4,694,122	US$8.4m	28.7%	no data
1.32%	Artisan Partners Limited Partnership	4,407,713	US$7.8m	-2.96%	0.01%
1.3%	T. Rowe Price Group, Inc.	4,334,100	US$7.7m	-48.8%	no data
1.07%	Morgan Stanley, Investment Banking and Brokerage Investments	3,570,525	US$6.4m	5.62%	no data
1.05%	Renaissance Technologies LLC	3,511,400	US$6.3m	0%	0.01%
1.05%	Dimensional Fund Advisors LP	3,506,108	US$6.2m	44.3%	no data
0.96%	Palo Alto Investors LP	3,211,314	US$5.7m	5.58%	1.18%
0.81%	MPM BioImpact LLC	2,708,582	US$4.8m	1.3%	0.78%
0.75%	Bank of America Corporation, Asset Management Arm	2,493,867	US$4.4m	688%	no data
0.72%	683 Capital Management, LLC	2,400,000	US$4.3m	69.5%	0.42%
0.7%	Northern Trust Global Investments	2,343,563	US$4.2m	-2.95%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/27 08:09
End of Day Share Price	2025/05/27 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Iovance Biotherapeutics, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Colleen Kusy	Baird
Madhu Kumar	Baird
Peter Lawson	Barclays